Research programme: siRNA hearing loss therapeutics - Quark Pharmaceuticals

Drug Profile

Research programme: siRNA hearing loss therapeutics - Quark Pharmaceuticals

Alternative Names: AHLi-11; QP-HL1; QP-HL2; QP-HL3

Latest Information Update: 17 Nov 2015

Price : $50

At a glance

  • Originator Quark Pharmaceuticals
  • Developer Quark Pharmaceuticals; State University of New York
  • Class Gene therapies; RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Meniere's disease; Noise-induced hearing loss; Sensorineural hearing loss
  • Research Hearing disorders

Most Recent Events

  • 17 Nov 2015 Early research in Hearing disorders in USA (Parenteral)
  • 06 Nov 2015 Preclinical trials in Meniere's disease in USA (Parenteral)
  • 25 Aug 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top